Kamada posts record first nine months 2026 and raises annual guidance
FROM THE WIRE · GLOBENEWSWIRE.COM
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe raised annual guidance is a positive signal for this mid-sized biopharma stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Kamada reported record results for the first nine months of 2026.
- 02The company increased its 2026 annual guidance.
- 03Kamada projects double-digit growth in revenues and profitability in 2027.
- 04A dividend payment was also announced.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets